NTRA - Natera, Inc.

FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Natera's MCED assay analyzes cell-free DNA in.

Oct 09, 2026 04:00 AM • businesswire.com

HWG Holdings LP Makes New $9.82 Million Investment in Natera, Inc. $NTRA

HWG Holdings LP acquired a new position in Natera, Inc. (NASDAQ: NTRA) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 23,772 shares of the medical research company's stock, valued at approximately $9,825,000. Natera comprises about 2.3% of

Oct 08, 2026 03:13 AM • defenseworld.net

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, an aggressive form of skin cancer. The current standard of care for these patients is combination immunotherapy until clinical pro.

Oct 07, 2026 04:00 AM • businesswire.com

Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why

Natera, Inc. (NASDAQ: NTRA - Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $429.97 and last traded at $430.7150, with a volume of 2233 shares trading hands. The stock had previously closed at $425.64. Analyst Upgrades and Downgrades A number of equities analysts recently commented on the stock.

Oct 06, 2026 06:00 AM • defenseworld.net

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Soci

Oct 06, 2026 05:00 AM • gurufocus.com

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera's first participation at ASTRO and a significant step in demonstrating Signatera's role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tum.

Oct 06, 2026 04:00 AM • businesswire.com

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cance.

Oct 05, 2026 04:00 AM • businesswire.com

Natera (NASDAQ:NTRA) CEO Sells 1,273 Shares of Company Stock

Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 1,273 shares of the business's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $413.31, for a total value of $526,143.63. Following the completion of the sale, the chief executive officer owned 96,926 shares in the

Oct 05, 2026 03:08 AM • defenseworld.net

Natera (NASDAQ: NTRA) insider sells 3,000 shares in a planned trade

What happened Natera, Inc. (NASDAQ: NTRA) insider Solomon Moshkevich sold 3,000 shares on 2026-10-01 under a Rule 10b5-1 trading plan. The Form 4 lists Moshkevich as PRESIDENT, CLINICALDIAGNOSTICS. The trades were all in common stock and were split into three sales. The tranches were 200 shares at $411.62, 954 shares at $413.1066, and 1,846 shares

Oct 04, 2026 03:32 AM • defenseworld.net

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

Sep 30, 2026 03:06 AM • etftrends.com

Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE:HPE).

Sep 28, 2026 03:38 AM • benzinga.com

Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx

NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.

Sep 23, 2026 08:16 AM • zacks.com

Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why

Natera, Inc. (NASDAQ: NTRA - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday. The stock traded as high as $371.59 and last traded at $366.2210, with a volume of 2446 shares changing hands. The stock had previously closed at $369.39. Trending Headlines about Natera Here are the key news

Sep 23, 2026 01:02 AM • defenseworld.net

3 Analysts, 3 Trades to Make Today

Louis says buy the AI dip

Sep 22, 2026 01:00 PM • investorplace.com

Uber, Micron, Datadog And A Health Care Stock: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, picked Uber Technologies, Inc. (NYSE:UBER).

Sep 22, 2026 04:24 AM • benzinga.com

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC). This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially.

Sep 22, 2026 04:00 AM • businesswire.com

Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript

Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript

Sep 21, 2026 06:29 AM • seekingalpha.com

Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 20, 2026 02:18 AM • seekingalpha.com

Natera CEO Steven Chapman Sells 1,698 Shares for $545,000

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

Sep 18, 2026 09:27 AM • fool.com

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the I

Sep 18, 2026 03:00 AM • gurufocus.com

Natera price target raised to $475 from $340 at Barclays

$475.00 (was $400.65)

Barclays

Oct 07, 2026 05:55 AM • TheFly

Natera price target raised to $475 from $360 at Guggenheim

$475.00 (was $418.12)

Guggenheim

Oct 01, 2026 08:28 AM • TheFly

Natera price target raised to $460 from $350 at RBC Capital

$460.00 (was $409.70)

RBC Capital

Sep 25, 2026 08:17 AM • TheFly

Natera assumed with a Buy at UBS

$435.00 (was $324.14)

UBS

Sep 09, 2026 07:22 AM • TheFly

Natera initiated with a Buy at Rothschild & Co Redburn

$385.00 (was $328.18)

Redburn Partners

Sep 08, 2026 05:14 AM • TheFly

Natera price target raised to $350 from $305 at Stephens

$350.00 (was $317.25)

Stephens

Aug 12, 2026 09:09 AM • TheFly

Natera price target raised to $360 from $290 at Guggenheim

$360.00 (was $312.72)

Guggenheim

Aug 12, 2026 06:47 AM • TheFly

Natera price target raised to $355 from $310 at Morgan Stanley

$355.00 (was $323.58)

Morgan Stanley

Aug 10, 2026 08:33 AM • TheFly

Natera price target raised to $350 from $275 at RBC Capital

$350.00 (was $316.14)

RBC Capital

Aug 07, 2026 08:24 AM • TheFly

Natera price target lowered to $348 from $379 at Baird

$348.00 (was $265.38)

Catherine Ramsey Schulte · Robert W. Baird

Aug 07, 2026 07:56 AM • TheFly

Natera price target raised to $375 from $330 at Canaccord

$375.00 (was $265.38)

Kyle Mikson · Canaccord Genuity

Aug 07, 2026 07:32 AM • TheFly

Natera price target raised to $284 from $220 at Wells Fargo

$284.00 (was $265.38)

Wells Fargo

Aug 07, 2026 07:09 AM • TheFly

Natera price target raised to $320 from $290 at BTIG

$320.00 (was $265.38)

BTIG

Aug 07, 2026 06:54 AM • TheFly

Natera price target raised to $330 from $280 at Leerink

$330.00 (was $265.38)

Leerink Partners

Aug 07, 2026 06:48 AM • TheFly

Natera price target raised to $340 from $260 at Barclays

$340.00 (was $265.38)

Barclays

Aug 07, 2026 06:05 AM • TheFly

Natera price target raised to $330 from $285 at Canaccord

$330.00 (was $272.89)

Canaccord Genuity

Jul 14, 2026 06:52 AM • TheFly

Natera price target raised to $310 from $250 at Morgan Stanley

$310.00 (was $274.39)

Morgan Stanley

Jul 09, 2026 06:58 AM • TheFly

Natera price target raised to $300 from $270 at Evercore ISI

$300.00 (was $281.26)

Evercore ISI

Jul 06, 2026 08:45 AM • TheFly

Natera price target raised to $290 from $270 at Guggenheim

$290.00 (was $261.91)

Subbu Nambi · Guggenheim

Jun 29, 2026 07:00 AM • TheFly

Natera price target raised to $275 from $270 at BTIG

$275.00 (was $260.72)

BTIG

Jun 24, 2026 01:00 PM • TheFly